Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …

Aim Four non‐vitamin K oral anticoagulants (NOAC s) have been evaluated in clinical trials
for the prevention of stroke in patients with atrial fibrillation (AF). Although each of the NOAC …

Dabigatran and rivaroxaban, direct oral anticoagulants (DOACs), affect coagulation tests,
and knowledge of their effects is important for therapeutic monitoring. Our aim was to …

Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly
increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke …

Background Strong evidence on the long-term safety and efficacy of different types of
anticoagulants would help clinicians to prevent thromboembolic events among patients with …

A large number of real world evidence (RWE) analyses have been published in the past few
years, including a retrospective analysis of outpatient data from Germany in this journal [1]; …